Your browser doesn't support javascript.
loading
Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients.
Cui, Cheng; Li, Xiaobei; Liang, Hao; Hou, Zhe; Tu, Siqi; Dong, Zhongqi; Yao, Xueting; Zhang, Miao; Zhang, Xuan; Li, Haiyan; Zuo, Xiaocong; Liu, Dongyang.
Afiliação
  • Cui C; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.
  • Li X; Institute of Medical Innovation, Peking University Third Hospital, Beijing, People's Republic of China.
  • Liang H; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.
  • Hou Z; School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
  • Tu S; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.
  • Dong Z; Institute of Medical Innovation, Peking University Third Hospital, Beijing, People's Republic of China.
  • Yao X; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.
  • Zhang M; Institute of Medical Innovation, Peking University Third Hospital, Beijing, People's Republic of China.
  • Zhang X; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.
  • Li H; School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
  • Zuo X; Janssen China R&D Center, Shanghai, People's Republic of China.
  • Liu D; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, People's Republic of China.
Biopharm Drug Dispos ; 42(1): 24-34, 2021 Jan.
Article em En | MEDLINE | ID: mdl-33340419
ABSTRACT
To preliminarily develop physiologically based population models for Chinese renal impairment patients and to evaluate the prediction performance of new population models by renally cleared antibacterial drugs. First, demographic data and physiological parameters of Chinese renal impairment patients were collected, and then the coefficients of the relative demographic and physiological equation were recalibrated to construct the new population models. Second, drug-independent parameters of ceftazidime, cefodizime, vancomycin, and cefuroxime were collected and verified by Chinese healthy volunteers, Caucasian healthy volunteers, and Caucasian renal impairment population models built in Simcyp. Finally, the newly developed population models were applied to predict the plasma concentration of four antibacterial drugs in Chinese renal impairment patients. The new physiologically based pharmacokinetic (PBPK) population models can predict the main pharmacokinetic parameters, including area under the plasma concentration-time curve extrapolated to infinity (AUCinf ), renal clearance (CLr ), and peak concentration (Cmax ), of ceftazidime, cefodizime, vancomycin, and cefuroxime following intravenous administrations with less than twofold error in mild, moderate, and severe Chinese renal impairment patients. The accuracy and precision of the predictions were improved compared with the Chinese healthy volunteers and Caucasian renal impairment population models. The PBPK population models were preliminarily developed and the first-step validation results of four antibacterial drugs following intravenous administration showed acceptable accuracy and precision. The population models still need more systematic validation by using more drugs and scenarios in future studies to support their applications on dosage recommendation for Chinese renal impairment patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência Renal / Rim / Antibacterianos Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência Renal / Rim / Antibacterianos Idioma: En Ano de publicação: 2021 Tipo de documento: Article